Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

a Multicenter, Randomized, Open Label Phase II Clinical Study to Evaluate the Safety and Efficacy of AK120 in the Treatment of Subjects With Moderate to Severe Atopic Dermatitis

NCT06092762 is registered in ClinicalTrials.gov with Akeso as lead sponsor.

NCT NCT06092762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06092762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
a Multicenter, Randomized, Open Label Phase II Clinical Study to Evaluate the Safety and Efficacy of AK120 in the Treatment of Subjects With Moderate to Severe Atopic Dermatitis
Lead sponsor
Akeso
Phase
Phase 2
Overall status
Completed
Start date
November 6, 2023
Completion date
November 13, 2024
Enrollment
180 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis